Localization of prostaglandin F2 alpha inhibition of lipoprotein use by bovine luteal cells.
Prostaglandin F2 alpha (PGF2 alpha) inhibits lipoprotein-stimulated progesterone production by bovine luteal cells in vitro and the objective of this study was to localize the site of action of PGF2 alpha. Cultured bovine luteal cells were treated with PGF2 alpha for seven days, and then with either lipoproteins or 25-hydroxycholesterol in the presence of aminoglutethimide (which inhibits cholesterol side-chain cleavage) for the final 48 h. The effects of PGF2 alpha on progesterone production, cellular cholesterol content, mitochondrial cholesterol content and cholesterol side-chain cleavage activity were determined. As expected, PGF2 alpha inhibited (P less than 0.05) lipoprotein-stimulated progesterone production. However, PGF2 alpha did not inhibit low-density lipoprotein-stimulated, or high density lipoprotein-stimulated, increases in cellular cholesterol (P less than 0.05) or inhibit lipoprotein-induced increases in mitochondrial cholesterol content (P less than 0.05). Additionally, cholesterol content of mitochondria increased (P less than 0.05) in the presence of PGF2 alpha alone. To determine if the PGF2 alpha-induced inhibition of steroidogenesis occurred at, or after, the side-chain cleavage reaction, we treated cells with the readily diffusable sterol, 25-hydroxycholesterol. Prostaglandin F2 alpha did not inhibit 25-hydroxycholesterol-stimulated progesterone production (P less than 0.05). Prostaglandin F2 alpha may therefore exert its luteolytic effect at a site after cholesterol transport to the mitochondria but before cholesterol side-chain cleavage.
Grusenmeyer
D P
DP
Department of Dairy Science, Ohio State University, Columbus 43210.
Pate
J L
JL
D000616:Aminoglutethimide / Q000378:metabolism; D000818:Animals; D002417:Cattle; D002478:Cells, Cultured; D002784:Cholesterol / Q000378:metabolism; D003338:Corpus Luteum / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D003864:Depression, Chemical; D015237:Dinoprost / Q000494:pharmacology*; D005260:Female; D006888:Hydroxycholesterols / Q000494:pharmacology; D008074:Lipoproteins / Q000378:metabolism*; D003341:Luteolysis / Q000502:physiology; D008928:Mitochondria / Q000378:metabolism; D011374:Progesterone / Q000096:biosynthesis
D006888:Hydroxycholesterols; D008074:Lipoproteins; D000616:Aminoglutethimide; D011374:Progesterone; C007997:25-hydroxycholesterol; D002784:Cholesterol; D015237:Dinoprost